UroToday.com - Men with benign prostatic hyperplasia (BPH) often suffer from lower urinary tract symptoms (LUTS; BPH-LUTS) such as urinary frequency, urgency, intermittency, nocturia, straining, incomplete emptying, or weak urinary stream. BPH-LUTS and erectile dysfunction (ED), both highly prevalent conditions in aging men, are frequently associated in the same men, may have common pathophysiological mechanisms, and contribute negatively to quality of life.
Phosphodiesterase type 5 (PDE5) isozymes are considered promising targets for drug intervention in the urogenital tract, and the potential use of PDE5 inhibitors as treatment for both BPH LUTS and ED is of clinical interest. The PDE5 inhibitor tadalafil, currently approved for the treatment of erectile dysfunction and for the treatment of pulmonary arterial hypertension in some geographies, is being studied in men with signs and symptoms of BPH. Tadalafil's 17.5-hour half-life makes it suitable for once-daily therapy.
We report a post hoc analysis of 581 men from a 12-week, randomized, double-blind, placebo-controlled, parallel-group, multinational, dose-finding study of once-daily tadalafil conducted in men with BPH-LUTS. The men included in this analysis were sexually active with a female partner and also had ED, defined as a consistent change in the quality of erection that adversely affected patient satisfaction with sexual intercourse.
Remainder of the article can be found at Medical News Today


